Transcranial Magnetic Stimulation (TMS): Clinical Reference

Transcranial Magnetic Stimulation is a non-invasive neuromodulation procedure that uses pulsed magnetic fields to induce electrical currents in targeted regions of the cerebral cortex. The U.S. Food and Drug Administration (FDA) has cleared TMS devices for specific psychiatric and neurological indications, making regulatory classification a practical consideration for any clinical discussion of the modality. This reference covers the mechanism of action, cleared indications, procedural structure, safety classification, and the clinical decision boundaries that distinguish TMS from comparable interventions such as Electroconvulsive Therapy (ECT) and Ketamine Therapy for Mental Health.

Definition and Scope

TMS delivers brief, high-intensity magnetic pulses — typically ranging from 1.5 to 4 Tesla at the coil surface — through a handheld electromagnetic coil placed against the scalp. These pulses penetrate the skull without direct electrical contact and depolarize cortical neurons in the targeted region. The term "transcranial" designates skull-penetrating delivery; "magnetic stimulation" designates the inductive rather than conductive mechanism.

The FDA first cleared a TMS device for major depressive disorder (MDD) in 2008 under the 510(k) premarket notification pathway (FDA 510(k) Database, K061053). Subsequent clearances extended the scope to include:

TMS devices are regulated under 21 CFR Part 882 (Neurological Devices) as Class II devices requiring special controls (Electronic Code of Federal Regulations, 21 CFR §882.5800). Class II status means the device does not require full premarket approval (PMA) but must demonstrate substantial equivalence to a predicate device.

For clinical context on the conditions TMS most commonly addresses, see Depression and Mood Disorders and Obsessive-Compulsive Disorder (OCD).

How It Works

Electromagnetic Induction Mechanism

A figure-eight or H-coil placed on the scalp carries a rapidly alternating electrical current. This current produces a magnetic field — orthogonal to the coil plane — that passes unimpeded through scalp and skull and induces a secondary electrical current in the underlying cortical tissue. This secondary current is sufficient to depolarize pyramidal neurons within approximately 2–3 centimeters of the coil surface for standard figure-eight configurations.

Frequency-Dependent Effects

The neurophysiological effect varies by stimulation frequency:

  1. High-frequency protocols (≥10 Hz) — generally increase cortical excitability in the targeted region; used to upregulate hypoactive areas (e.g., left dorsolateral prefrontal cortex in MDD)
  2. Low-frequency protocols (≤1 Hz) — generally suppress cortical excitability; used to inhibit overactive regions (e.g., right dorsolateral prefrontal cortex in some depression protocols)
  3. Theta Burst Stimulation (TBS) — a compressed protocol delivering triplet bursts at 50 Hz, repeated at 5 Hz intervals; the FDA cleared a TBS protocol in 2018 that delivers a full session in approximately 3 minutes versus the 37-minute standard protocol

Standard Treatment Course

A conventional TMS course for MDD follows a structured sequence:

  1. Motor threshold determination — a baseline calibration step to individualize pulse intensity to approximately 120% of the resting motor threshold
  2. Coil positioning — typically targeting the left dorsolateral prefrontal cortex (L-DLPFC) using scalp landmarks or neuronavigation
  3. Daily sessions — 5 sessions per week for 4–6 weeks (20–30 total sessions)
  4. Maintenance protocols — variable; no universal standard has been established by regulatory guidance
  5. Response assessment — clinician-rated scales (e.g., HAM-D, PHQ-9) used to track symptom trajectory

The American Psychiatric Association's Practice Guidelines and the Clinical TMS Society's published protocols both inform practitioner standards for session parameters, though neither constitutes a federal regulatory mandate.

Common Scenarios

TMS appears most frequently in three clinical contexts within the Outpatient Mental Health Services continuum:

Treatment-Resistant Depression: The most established use. Patients who have not achieved remission after an adequate trial of at least one antidepressant — a threshold sometimes operationalized as two failed trials at therapeutic dose and duration — are the primary target population identified in FDA clearance language. Response rates in pivotal trials submitted to the FDA ranged from 20% to 30% for remission and approximately 40% to 50% for response (defined as ≥50% symptom reduction) (FDA Summary of Safety and Effectiveness, K061053).

OCD Augmentation: The 2018 OCD clearance specifies the H7 coil configuration targeting the medial prefrontal cortex and anterior cingulate cortex. This indication is additive — used in conjunction with pharmacotherapy and behavioral treatment (Cognitive-Behavioral Therapy (CBT)) rather than as a standalone replacement.

Anxious Depression: The 2021 clearance for anxious depression used a protocol targeting the right DLPFC with low-frequency suppression in addition to the standard left-sided excitatory protocol — a bilateral approach distinguishing it from earlier single-site protocols.

Decision Boundaries

TMS vs. ECT

TMS and ECT are both neuromodulation procedures, but they differ across five clinically significant dimensions:

Feature TMS ECT
Seizure induction Not intended; seizure is an adverse event Intentional generalized seizure
Anesthesia required No Yes (general anesthesia)
Cognitive side effects Minimal at approved parameters Memory impairment documented
Acuity of indication Moderate; outpatient setting Severe or acute; often inpatient
Regulatory class (US) Class II device Class II device (post-2018 reclassification)

ECT retains a stronger evidence base for acute suicidality and psychotic depression. For reference, Suicidality and Crisis Intervention and Inpatient Psychiatric Care Explained cover the clinical pathways where ECT is typically prioritized over TMS.

Contraindications and Risk Classification

The FDA-cleared device labeling identifies absolute contraindications:

Relative contraindications include a personal or family history of epilepsy, active substance use disorders, and pregnancy — none of which constitute absolute exclusions but require documented risk-benefit analysis by a qualified prescriber.

The most serious documented adverse event is seizure induction, occurring at an estimated rate of less than 1 in 30,000 sessions in published safety datasets (Rossi et al., "Safety, ethical considerations, and application guidelines for the use of TMS in clinical practice," Clinical Neurophysiology, 2009 — indexed in PubMed, PMID 19833552). Transient headache and scalp discomfort are the most common non-serious adverse events, reported in approximately 20–40% of patients across major trials.

Regulatory Reimbursement Boundaries

Medicare covers TMS for treatment-resistant MDD under Local Coverage Determination (LCD) L36469, administered by CMS contractors (CMS LCD L36469). Coverage requires documented failure of at least 1 antidepressant trial during the current depressive episode. Medicaid coverage varies by state and is not federally mandated for TMS. For coverage structure, Mental Health Insurance Coverage US and Medicaid and Mental Health Services provide the relevant framework.

References

Explore This Site

Regulations & Safety Regulatory References Tools & Calculators Bmi Health Metrics Calculator